Back to Screener

DaVita Inc. (DVA)

Price$192.16
Value ScoreC
Growth ScoreC
Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)52.64%
Price vs S&P 500 (4W)-3.26%
VGM Score59.80
Market Capitalization$12.34B
P/E Ratio (Annual)16.52x

All Metrics

P/CF (Annual)6.54x
Book Value / Share (Quarterly)$1.50
P/TBV (Annual)11.21x
Revenue Growth (3Y)5.53%
Cash Flow / Share (Quarterly)$22.55
Price vs S&P 500 (YTD)60.98%
Gross Margin (TTM)32.45%
Net Profit Margin (TTM)5.65%
EPS (TTM)$10.77
10-Day Avg Trading Volume0.71M
EPS Excl Extra (TTM)$10.77
Revenue Growth (5Y)3.39%
EPS (Annual)$9.84
ROI (Annual)9.79%
Gross Margin (Annual)32.25%
Net Profit Margin (5Y Avg)6.34%
Cash / Share (Quarterly)$10.07
P/E Basic Excl Extra (TTM)15.79x
Revenue Growth QoQ (YoY)5.96%
EPS Growth (5Y)9.36%
P/E Normalized (Annual)16.52x
ROA (Last FY)4.27%
Revenue Growth TTM (YoY)6.68%
EBITD / Share (TTM)$38.31
ROE (5Y Avg)220.50%
Operating Margin (TTM)14.98%
Cash Flow / Share (Annual)$19.12
P/B Ratio101.85x
P/B Ratio (Quarterly)101.25x
Net Income / Employee (Annual)$9,600
EV / Revenue (TTM)1.61x
Net Interest Coverage (TTM)3.46x
ROA (TTM)4.46%
EPS Growth QoQ (YoY)43.07%
EV / EBITDA (TTM)8.00x
EPS Incl Extra (Annual)$9.84
Current Ratio (Annual)1.29x
Quick Ratio (Quarterly)1.31x
3-Month Avg Trading Volume1.00M
52-Week Price Return39.51%
EV / Free Cash Flow (Annual)17.03x
P/E Incl Extra (TTM)15.79x
Revenue / Employee (TTM)$177,400
Tangible BV / Share (Quarterly)$2.29
P/S Ratio (Annual)0.90x
Asset Turnover (Annual)0.78x
52-Week High$202.69
Operating Margin (5Y Avg)14.24%
EPS Excl Extra (Annual)$9.84
CapEx CAGR (5Y)-3.11%
Tangible BV CAGR (5Y)-24.96%
26-Week Price Return60.56%
Quick Ratio (Annual)1.19x
13-Week Price Return28.16%
Total Debt / Equity (Annual)77.99x
Current Ratio (Quarterly)1.42x
Enterprise Value$22.32B
Revenue / Share Growth (5Y)13.87%
Asset Turnover (TTM)0.79x
Book Value / Share Growth (5Y)-38.38%
Revenue / Employee (Annual)$174,900
Inventory Turnover (Annual)62.63x
Pretax Margin (Annual)9.87%
Cash / Share (Annual)$10.22
3-Month Return Std Dev53.19%
Gross Margin (5Y Avg)31.46%
Net Income / Employee (TTM)$10,000
EBITDA CAGR (5Y)4.19%
EBITDA Interim CAGR (5Y)1.64%
ROE (Last FY)773.06%
Net Interest Coverage (Annual)3.53x
EPS Basic Excl Extra (Annual)$9.84
P/FCF (TTM)8.26x
Receivables Turnover (TTM)5.79x
EV / Free Cash Flow (TTM)14.95x
Total Debt / Equity (Quarterly)77.99x
EPS Incl Extra (TTM)$10.77
Receivables Turnover (Annual)5.37x
ROI (TTM)9.56%
P/S Ratio (TTM)0.89x
Pretax Margin (5Y Avg)10.58%
Revenue / Share (Annual)$179.79
Tangible BV / Share (Annual)$9.60
Forward P/E13.07x
Free OCF CAGR (5Y)0.09%
Price vs S&P 500 (52W)15.14%
P/E Ratio (TTM)15.79x
EPS Growth TTM (YoY)6.61%
Year-to-Date Return69.14%
5-Day Price Return1.24%
EPS Normalized (Annual)$9.84
ROA (5Y Avg)4.56%
Net Profit Margin (Annual)5.47%
Month-to-Date Return-1.13%
Cash Flow / Share (TTM)$17.04
EBITD / Share (Annual)$36.17
EPS Growth (3Y)19.05%
Operating Margin (Annual)14.88%
LT Debt / Equity (Annual)75.76x
P/CF (TTM)6.09x
ROI (5Y Avg)8.24%
P/E Excl Extra (TTM)15.79x
LT Debt / Equity (Quarterly)75.76x
EPS Basic Excl Extra (TTM)$10.77
P/TBV (Quarterly)71.72x
P/B Ratio (Annual)101.25x
Inventory Turnover (TTM)63.98x
Pretax Margin (TTM)10.13%
Book Value / Share (Annual)$1.50
Price vs S&P 500 (13W)19.90%
Net Margin Growth (5Y)-3.98%
Beta0.92x
P/FCF (Annual)9.41x
Revenue / Share (TTM)$200.87
ROE (TTM)181.22%
52-Week Low$101.00
vGradeC
gGradeC
mGradeB
vgmGradeC
Show chart for

Earnings Surprise History

Q1 262.87est. 2.34

Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
2.65
3.36
3.43
3.43

About

DaVita is the largest U.S. dialysis provider, operating over 3,000 facilities globally and treating approximately 280,000 patients annually, with roughly 35% of U.S. market share. The company derives about two-thirds of U.S. sales from government payers (primarily Medicare) at regulated reimbursement rates. Though commercial insurers represent only 10% of U.S. patients served, they generate nearly all profits from the U.S. dialysis business, creating significant earnings sensitivity to commercial payer mix.